Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.
Int J Med Sci
; 17(7): 892-902, 2020.
Article
in En
| MEDLINE
| ID: mdl-32308542
ABSTRACT
Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Hepacivirus
/
Hepatitis C, Chronic
Limits:
Humans
Language:
En
Journal:
Int J Med Sci
Journal subject:
MEDICINA
Year:
2020
Document type:
Article
Affiliation country:
China